Download PDF
Thromb Haemost 1982; 47(03): 226-229
DOI: 10.1055/s-0038-1657173
Original Article
Schattauer GmbH Stuttgart

Pharmacological Studies on the Antithrombotic Action of Hirudin in Experimental Animals

F Markwardt
The Institute of Pharmacology and Toxicology, Medical Academy Erfurt, Erfurt, G. D. R.
,
J Hauptmann
The Institute of Pharmacology and Toxicology, Medical Academy Erfurt, Erfurt, G. D. R.
,
G Nowak
The Institute of Pharmacology and Toxicology, Medical Academy Erfurt, Erfurt, G. D. R.
,
Ch Kleßen
The Institute of Pharmacology and Toxicology, Medical Academy Erfurt, Erfurt, G. D. R.
,
P Walsmann
The Institute of Pharmacology and Toxicology, Medical Academy Erfurt, Erfurt, G. D. R.
› Author Affiliations
Further Information

Publication History

Received 19 January 1982

Accepted 19 March 1982

Publication Date:
13 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The pharmacodynamics and pharmacokinetics of hirudin were studied in dogs, rabbits and rats. Hirudin proved to be a well tolerated substance with low toxicity. After intravenous injection it was eliminated with a half time of 50 to 60 min. It was nearly completely excreted through the kidneys in biologically active form. The efficacy of hirudin in preventing venous thrombosis, vascular shunt occlusion and disseminated intravascular coagulation in rats was demonstrated.

Key words

Hirudin - Pharmacodynamics - Pharmacokinetics - Antithrombotic effect
 

  • References

  • 1 Markwardt F. Untersuchungen über Hirudin. Naturwissenschaften 1955; 42: 537-538
    PubMedGoogle Scholar
  • 2 Markwardt F. Untersuchungen über den Mechanismus der blutgerinnungshemmenden Wirkung des Hirudins. Arch Exp Pathol 1956; 229: 389-399
    PubMedGoogle Scholar
  • 3 Markwardt F. Die Isolierung und chemische Charakterisierung des Hirudins. Hoppe Seylers Z Physiol Chem 1957; 308: 147-156
    CrossrefPubMedGoogle Scholar
  • 4 Markwardt F. Versuche zum Reaktionsmechanismus des Hirudins. Arch Exp Pathol 1957; 232: 343-345
    PubMedGoogle Scholar
  • 5 Bagdy D, Barabas E, Graf L, Peterson TE, Magnusson S. Hirudin. In: Methods in Enzymology. vol. 45B: Proteolytic Enzymes Lorand L. (ed.) 669-678 Academic Press New York, San Francisco; London: 1976
    Google Scholar
  • 6 Markwardt F. Blutgerinnungshemmende Wirkstoffe aus blutsaugenden Tieren. Fischer, Jena 1963
    PubMedGoogle Scholar
  • 7 Markwardt F. Hirudin as an inhibitor of thrombin. In: Methods in Enzymology. vol. 19: Proteolytic Enzymes Perlmann GE, Lorand L. Academic Press New York; London: 1970
    Google Scholar
  • 8 Walsmann P, Markwardt F. Biochemische und pharmakologische Aspekte des Thrombininhibitors Hirudin. Pharmazie 1981; 36: 653-660
    PubMedGoogle Scholar
  • 9 Markwardt F. Versuche zur pharmakologischen Charakterisierung des Hirudins. Arch Exp Pathol 1958; 234: 516-529
    PubMedGoogle Scholar
  • 10 Markwardt F. Über den Einfluß des Hirudins auf die Thrombenbildung. Arch Exp Pathol 1959; 236: 286-288
    PubMedGoogle Scholar
  • 11 Markwardt F, Landmann H. Blutgerinnungshemmende Proteine, Peptide und Aminosäurederivate. In: Handbuch der experimentellen Pharmakologi. vol.27: Antikoagulantien Markwardt F. (ed.) 76-142 Springer Berlin, Heidelberg; New York: 1971
    Google Scholar
  • 12 Markwardt F, Schäfer G, Töpfer H, Walsmann P. Die Isolierung des Hirudins aus medizinischen Blutegeln. Pharmazie 1967; 22: 239-241
    PubMedGoogle Scholar
  • 13 Walsmann P. Untersuchungen zur Affinitätschromatografie an trägerfixiertem Thrombin. Pharmazie 1981; 36: 860-861
    PubMedGoogle Scholar
  • 14 Markwardt F, Walsmann P. Die Reaktion zwischen Hirudin und Thrombin. Hoppe Seylers Z Physiol Chem 1958; 312: 85-98
    CrossrefPubMedGoogle Scholar
  • 15 Markwardt F, Walsmann P. Reindarstellung und Analyse des Thrombininhibitors Hirudin. Hoppe Seylers Z Physiol Chem 1967; 348: 1381-1386
    CrossrefPubMedGoogle Scholar
  • 16 Markwardt F, Nowak G, Meerbach W, Rüdiger KD. Studies in experimental animals on disseminated intravascular coagulation (DIC). Thrombos Diathes Haemorrh 1975; 34: 513-521
    PubMedGoogle Scholar
  • 17 Koth W, Nowak G, Markwardt F. Monitoring of microthrombosis in experimental animals by continuous recording of 125I-fibrin deposits and 51Cr-labelled platelets in the lungs. Acta Biol Med Ger 1980; 39: 157-162
    PubMedGoogle Scholar
  • 18 Klöss T, Lorenz W, Meyer U, Mittmann U, Neugebauer E, Saggau WW. Gerinnungshemmung durch selektive Thrombinblockade mit Hirudin. Langenbecks Arch Chir Suppl 1978; 143-148
    PubMedGoogle Scholar
  • 19 Markwardt F, Nowak G, Hoffmann J. The influence of drugs on disseminated intravascular coagulation (DIC). II. Effects of naturally occurring and synthetic thrombin inhibitors. Thromb Res 1977; 11: 275-283
    CrossrefPubMedGoogle Scholar
  • 20 Haustein KO, Markwardt F. Über den Einfluß von Hemmstoffen der Blutgerinnung und Fibrinolyse auf das Sanarelli-Shwartzman-Phänomen. Thrombos Diathes Haemorrh 1965; 13: 60-64
    PubMedGoogle Scholar
  • 21 Haustein KO, Markwardt F. Versuche zur pharmakologischen Beeinflussung des lokalisierten Sanarelli-Shwartzman-Phänomens. Folia Haematol (Leipz) 1972; 97: 104-108
    PubMedGoogle Scholar
  • 22 Ishikawa A, Hafter R, Seemüller U, Gokel JM, Graeff H. The effect of hirudin on endotoxin induced disseminated intravascular coagulation (DIC). Thromb Res 1980; 19: 351-358
    CrossrefPubMedGoogle Scholar
  • 23 Nowak G, Markwardt F. Influence of hirudin on endotoxin-induced disseminated intravascular coagulation (DIC) in weaned pigs. Exp Pathol (Jena) 1980; 18: 438-443
    PubMedGoogle Scholar